Abstract
Background and AimsIn late 2019, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged in Wuhan, China. Rapid global spread led to the coronavirus disease 2019 (Covid‐19) pandemic. Accurate detection of SARS‐CoV‐2 has become a vitally important tool in controlling the spread of the virus. Lateral flow devices (LFDs) offer the potential advantage of speed and on‐site testing. The sensitivity of these devices compared to reverse transcription‐polymerase chain reaction (RT‐PCR) has been questioned.MethodsWe compared the sensitivity of the Innova LFD, used widely in the United Kingdom, with our rapid RT‐PCR method using stored positive samples. Samples with a range of viral loads (original Ct values 18.9–36.5) were tested.ResultsThe Innova LFD was found to be 6000–10,000 times less sensitive than RT‐PCR for SARS‐CoV‐2 detection. Overall, the LFD detected 46.2% of the positives detected by RT‐PCR, with 50% of these observed to be weak LFD positives. At lower viral loads, such as 10,000–100,000 RNA copies/ml, the LFD detected 22.2% of positives. In addition, two strong positives (3 and 1.5 million RNA copies/ml) were not detected by the LFD.ConclusionThe argument for use of LFD kits is that they detect infectious virus and hence contagious individuals. However, there is a lack of conclusive evidence supporting this claim. The Innova LFD has been subject to a Class I recall by the US Food and Drug Administration, but is still approved and widely used in the United Kingdom.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.